araag2/HINT huggingface dataset:
Clinical trial NCT00143507 (phase 3, status: completed)
Conditions: coronary disease, ventricular dysfunction, left
ICD codes: I25.10, I25.110, I25.119, I25.111, I25.118, I47.2, I49.01, I49.02, I49.3, Q21.0, I47.0, I50.1
Drugs: ivabradine, placebo
SMILES: COC1=C(OC)C=C2[C@@H](CN(C)CCCN3CCC4=CC(OC)=C(OC)C=C4CC3=O)CC2=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Coronary artery disease

          -  Left ventricular systolic dysfunction

          -  Sinus rhythm: heart rate (HR) >= 60 beats per minute (bpm)

        Exclusion Criteria:

          -  Unstable cardiovascular condition

          -  Severe congestive heart failure
Clinical trial NCT00104715 (phase 3, status: completed)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: antiandrogen therapy, docetaxel, goserelin acetate
SMILES: CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC(=C(C=C1)C#N)C(F)(F)F, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed prostate adenocarcinoma

               -  Metastatic disease

          -  Measurable or evaluable disease

          -  No brain metastases

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  ECOG 0-2

        Life expectancy

          -  At least 3 months

        Hematopoietic

          -  WBC ≥ 2,000/mm^3

          -  Absolute neutrophil count ≥ 1,000/mm^3

          -  Platelet count ≥ 100,000/mm^3

        Hepatic

          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN) (2.5 times normal if hepatic
             metastases are present)

          -  AST and ALT ≤ 1.5 times ULN (2.5 times normal if hepatic metastases are present)

        Renal

          -  Creatinine ≤ 150 μmol/L

        Cardiovascular

          -  No symptomatic coronary disease

          -  No congenital cardiac insufficiency

          -  No New York Heart Association class III or IV cardiovascular disease

          -  No other severe cardiovascular disease

        Other

          -  No severe peripheral neuropathy

          -  No active infection

          -  No other malignancy within the past 5 years except basal cell skin cancer

          -  No familial, social, geographical, or psychological situation that would preclude
             study compliance and follow-up

          -  No other serious disease that would preclude study participation

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  No prior chemotherapy for metastatic prostate cancer

          -  Prior chemotherapy allowed provided all of the following are true:

               -  Chemotherapy was completed > 1 year ago

               -  Prostate-specific antigen level has remained stable

               -  No development of metastases within 1 year after completion of chemotherapy

        Endocrine therapy

          -  Prior hormonal therapy within the past 2 months allowed for metastatic prostate cancer

        Radiotherapy

          -  More than 4 weeks since prior radiotherapy to metastatic sites

        Surgery

          -  No prior surgical castration

        Other

          -  No other concurrent investigational drugs
Clinical trial NCT00210548 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: paliperidone palmitate
SMILES: CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
Eligibility criteria:

        Inclusion Criteria:

          -  A DSM-IV diagnosis of schizophrenia (disorganized, catatonic, paranoid, residual, or
             undifferentiated type) for at least 1 year before the screening evaluation

          -  a total PANSS score of 70 to 120 at screening and baseline (pre-treatment) evaluations

          -  a body mass index (BMI [weight (kilograms)]/[height (meters)]²) of more than 17.0
             kg/m²

        Exclusion Criteria:

          -  A primary active DSM-IV Axis I diagnosis other than schizophrenia

          -  a decrease of 25% or more in the total PANSS score between screening and baseline
             evaluations

          -  a DSM-IV diagnosis of active substance dependence within 3 months of screening
             evaluation

          -  a history of treatment resistance as defined by failure to respond to 2 adequate
             trials of different antipsychotic medications

          -  a woman who is pregnant, breast-feeding, or planning to become pregnant during the
             study period.
Clinical trial NCT00144339 (phase 3, status: completed)
Conditions: pulmonary disease, chronic obstructive
ICD codes: J44.9, J44.1, J44.0
Drugs: tiotropium, placebo
SMILES: [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Written informed consent.

          -  Male or female patients 40 years of age or older.

          -  Smoking history of at least 10 pack years.

          -  Diagnosis of COPD with post bronchodilator FEV1 less than or equal to 70% of predicted
             normal and FEV1<70% of FVC and on stable respiratory medication.

        Exclusion Criteria:

          -  Significant diseases other than COPD which in the opinion of the investigator may put
             the patient at risk or influence the patients ability to participate.

          -  Myocardial infarction in past 6 months.

          -  Unstable or life threatening arrhythmia in past year.

          -  Hospitalization for NYHA heart failure class III or IV in past year.

          -  Active tuberculosis.

          -  Asthma.

          -  Pulmonary resection.

          -  Malignancy treated with radiation or chemotherapy in past 5 years.

          -  Respiratory infection in 4 weeks prior to screening.

          -  Known hypersensitivity to anticholinergic drugs or components.

          -  Known moderate to severe renal impairment.

          -  Known narrow angle glaucoma.

          -  Significant symptomatic BPH or bladder neck obstruction.

          -  Need for oxygen therapy >12 hr/day.

          -  Use of oral corticosteroids at unstable doses or >10 mg/day.
Clinical trial NCT02736721 (phase 3, status: completed)
Conditions: myelogenous leukemia, chronic
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: peginterferon alfa-2a
SMILES: NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Participants with CML

          -  Previous participation in studies: ML16544, NO16006 or ML17228; for which the treating
             physician recommends a continuation of the study drug according to defined minimal
             criteria

        Exclusion Criteria:

          -  Major protocol violator in the participated study prior to participation in this study
Clinical trial NCT00319111 (phase 3, status: completed)
Conditions: pulmonary hypertension
ICD codes: I27.0, I27.20, I27.21, I27.24, I27.29, P29.30, I27.22
Drugs: bosentan
SMILES: COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)N=C(N=C1OCCO)C1=NC=CC=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients having completed the 16-week treatment period of protocol AC-052-366
             (NCT00313222)

          -  Signed informed consent

        Exclusion Criteria:

          -  Any major violation of protocol AC-052-366 (NCT00313222)

          -  Pregnancy or breast-feeding
Clinical trial NCT00392262 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: valsartan + amlodipine
SMILES: CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          1. Male or female patients (18 years)

          2. Patients with moderate essential hypertension (untreated must have MSSBP ≥160 and <180
             mmHg at Visit 1, treated must have MSSBP <180 mmHg at Visit 1) (WHO grade II)

        Exclusion Criteria:

          1. Severe hypertension(MSDBP ≥110 mmHg or MSSBP ≥ 180 mmHg)

          2. Pregnant or nursing women

          3. Treated hypertensive patients with controlled hypertension under current therapy
             (diastolic BP < 90 mmHg and systolic BP < 140 mmHg)

          4. A history of cardiovascular disease, including angina pectoris, myocardial infarction,
             coronary artery bypass graft, percutaneous transluminal coronary angioplasty,
             transient ischemic attack, stroke, and heart failure NYHA II - IV

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT00099437 (phase 3, status: active, not recruiting)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: fulvestrant
SMILES: [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Breast Cancer has continued to grow after having received treatment with an
             anti-estrogen hormonal treatment such as tamoxifen or an aromatase inhibitor

          -  Requiring hormonal treatment

          -  Postmenopausal women defined as a woman who has stopped having menstrual periods

          -  Evidence of positive estrogen receptor hormone sensitivity

          -  Written informed consent to participate in the trial

        Exclusion Criteria:

          -  Treatment with an investigational or non-approved drug within one month

          -  An existing serious disease, illness, or condition that will prevent participation or
             compliance with study procedures

          -  A history of allergies to any active or inactive ingredients of Faslodex (i.e. castor
             oil)

          -  Treatment with more than one regimen of chemotherapy for advanced breast cancer

          -  Treatment with more than one regimen of hormonal treatment for advanced breast cancer
Clinical trial NCT01716585 (phase 3, status: completed)
Conditions: chronic hepatitis c infection
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: abt-450/r/abt-267, abt-333, ribavirin, placebo for abt-450/r/abt-267, placebo for abt-333, placebo for ribavirin
SMILES: CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Females must be post-menopausal for at least 2 years or surgically sterile or
             practicing specific forms of birth control

          -  Chronic hepatitis C, genotype 1-infection and HCV RNA level greater than 10,000 IU/mL
             at screening

          -  Subject has never received antiviral treatment for hepatitis C infection

          -  No evidence of liver cirrhosis

        Exclusion Criteria:

          -  Positive screen for drugs or alcohol

          -  Significant sensitivity to any drug

          -  Use of contraindicated medications within 2 weeks of dosing

          -  Certain predefined abnormal laboratory tests

          -  Positive hepatitis B surface antigen or anti-human immunodeficiency virus antibody
Clinical trial NCT00525096 (phase 3, status: completed)
Conditions: metastatic breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: placebo, celecoxib, exemestane
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, COC1=CC=C(C=C1)C(=O)CC(=O)C1=CC=C(C=C1)C(C)(C)C, CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N
Eligibility criteria:

        Inclusion Criteria:

          -  Femal patient aged > 18 years

          -  Histologically proven breast cancer

          -  Menopausal patient according to the following definition:

               -  amenorrhoea > 1 year or menopause affirmed by a rate of oestradiol or hypophyseal
                  gonadotrophin

               -  surgical ovariectomy

               -  treatment by LHRH analog

               -  ovarian suppression by radiotherapy

               -  amenorrhoea induced by chemotherapy > 1 year

          -  Oestradiol and/or progesterone positive receptors

          -  Presence of one or several metastatic lesion:

               -  mesurable lesion

               -  bone metastase were detected by bone scintigraphy

          -  Patient who can have received:

               -  Adjuvant chemotherapy and/or hormonotherapy (Tamoxifen)

               -  Metastatic Treatment by chemotherapy

          -  PS < 2

          -  Adequate biological values

          -  Patient who has clearly given her consent by signing on informed consent form prior to
             participation

        Exclusion Criteria:

          -  Patient previously treated with hormonotherapy in metastatic phase

          -  Antecedent of treatment with aromatase inhibitors

          -  local relapse (with the exception of cutaneous thoracic nodes)

          -  Patient with only one metastatic lesion like: pleurisy , ascites, lung Lymphangitis
             carcinomatosa
Clinical trial NCT00108979 (phase 3, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: escitalopram
SMILES: CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must meet Diagnostic and Statistical Manual, Fourth Edition (DSM-IV)
             diagnostic criteria for Major Depressive Disorder.

          -  The patient's current depressive episode must be at least 12 weeks in duration.

        Exclusion Criteria:

          -  Women who are pregnant, women who will be breastfeeding during the study, and women of
             childbearing potential who are not practicing a reliable method of birth control.

          -  Patients who currently meet DSM-IV criteria for: a. bipolar disorder; b. schizophrenia
             or any psychotic disorder; c. obsessive-compulsive disorder; d. mental retardation or
             any pervasive developmental disorder or cognitive disorder.

          -  Patients who are considered a suicide risk.

          -  Patients with a history of seizure disorder, or any history of seizure, stroke,
             significant head injury, or any other condition that predisposes toward risk of
             seizure.
Clinical trial NCT00075725 (phase 3, status: unknown status)
Conditions: leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, doxorubicin hydrochloride, leucovorin calcium, mercaptopurine, methotrexate, pegaspargase, prednisone, thioguanine, vincristine sulfate
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1, S=C1N=CNC2=C1NC=N2, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, N[C@@H](CC1=CN=CN1)C(O)=O, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, NC1=NC(=S)C2=C(N1)N=CN2, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Newly diagnosed B-precursor acute lymphoblastic leukemia

               -  WBC > 50,000/mm^3 for patients age 1 to 9

               -  Any WBC for patients age 10 to 30 OR patients who have received prior steroid
                  therapy OR patients with testicular disease

          -  Must be eligible for and enrolled on classification study COG-AALL03B1

        PATIENT CHARACTERISTICS:

        Age

          -  1 to under 31

        Performance status

          -  Not specified

        Life expectancy

          -  Not specified

        Hematopoietic

          -  See Disease Characteristics

        Hepatic

          -  Not specified

        Renal

          -  Not specified

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  No more than 72 hours since prior intrathecal cytarabine

          -  No other prior cytotoxic chemotherapy

        Endocrine therapy

          -  Prior steroids allowed

        Radiotherapy

          -  Not specified

        Surgery

          -  Not specified
Clinical trial NCT00562965 (phase 3, status: terminated)
Conditions: lymphoma, follicular
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: inotuzumab ozogamicin, rituximab, rituximab, cyclophosphamide, vincristine, prednisone/prednisolone, mitoxantrone, fludarabine, dexamethasone
SMILES: CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(C(O)=CC=C1O)C2=O, ClCCN(CCCl)P1(=O)NCCCO1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Reason stopped: 
    see termination reason in detailed description.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects with a diagnosis of CD20 and CD22-positive, follicular lymphoma, who have
             received 1 or 2 prior regimens, at least 1 of which should have contained
             administration of rituximab (either as a single agent or in combination).

          -  Age 18 years or older.

          -  ECOG performance status <= 2.

          -  ANC >= 1.5 x 10^9/L (1500/mL) and platelets >= 75 x 10^9/L (75,000/mL), serum
             creatinine <= 1.5 x ULN and urine protein to creatinine ratio of <= 0.5, total
             bilirubin <= 1.5 x ULN, AST and ALT <= 2.5 x ULN.

          -  At least 1 measurable disease lesion that is >= 1.5 cm x 1.5 cm by CT or MRI, in an
             area of no prior radiation therapy, or documented progression in an area that was
             previously irradiated.

        Exclusion Criteria:

          -  Subjects with clinical evidence of transformation to a more aggressive subtype of
             lymphoma or grade 3b follicular lymphoma.

          -  Subjects whose disease is rituximab refractory, meaning that they did not have a CR or
             PR, or that they experienced disease progression within 6 months from the initiation
             of the rituximab or rituximab containing treatment regimen administered immediately
             preceding study enrollment.
Clinical trial NCT00212784 (phase 3, status: completed)
Conditions: schizophrenia, schizoaffective disorder
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9, F25.9, F25.0, F25.1, F25.8
Drugs: asenapine, olanzapine
SMILES: OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1, CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Subject with schizophrenia or schizoaffective disorder. Subject must sign a written
             informed consent.

        Exclusion Criteria:

          -  Have an uncontrolled, unstable, clinically significant medical condition. Have any
             other psychiatric disorder other than schizophrenia as a primary diagnosis including
             depression.
Clinical trial NCT01272908 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: rituximab
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients, 18-80 years of age

          -  Moderate to severe active rheumatoid arthritis

          -  Inadequate response to a single previous or current treatment with an anti-TNF agent

          -  Methotrexate for at least 12 weeks, at a stable dose over the past 4 weeks

        Exclusion Criteria:

          -  Previous treatment with MabThera

          -  Use of an anti-TNF agent within past 8 weeks (4 in the case of etanercept)

          -  Concurrent treatment with any Disease Modifying Anti-Rheumatic Drug (DMARD) other than
             methotrexate

          -  Active infection, or history of serious or chronic infection
Clinical trial NCT00151827 (phase 3, status: completed)
Conditions: essential hypertension, renal impairment
ICD codes: I10, O10.02, O10.03, O10.011, O10.012, O10.013, O10.019, M10.38, M10.30, M10.311, M10.312, M10.319, M10.321, M10.322
Drugs: olmesartan medoxomil, losartan, furosemide oral tablets
SMILES: CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O, CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1, NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Mean sitting BP prior to randomization of 140-180/90-109 mmHg;

          -  Renal impairment prior to randomization of mild (50 ≤ CLcr ≥ 80 mL/min) to moderate
             (30 ≤ CLcr ≥50 mL/min) severity

        Exclusion Criteria:

          -  Malignant hypertension or sitting BP greater than 180/109 mmHg;

          -  Severe heart failure, severe renal disease;

          -  Recent history of myocardial infarction, stroke or transient ischemic attack;

          -  History, clinical or current evidence of any significant gastrointestinal,
             respiratory, hematological, metabolic, immunological or any other underlying disease
             which in the opinion of the investigator would interfere with the patient's
             participation in the trial;

          -  Hypersensitivity or contraindications to ARBs or ACE inhibitors or any cross allergy;

          -  Treatment with dis-allowed medication;

          -  Pregnant or breastfeeding females or females of childbearing potential without
             adequate contraception;

          -  History of drug and/or alcohol abuse